What is SpeeDx?
Founded in 2009, SpeeDx has evolved into a pivotal player in the diagnostic landscape, specializing in the detection of viral and bacterial infections alongside complex antibiotic resistance markers. The company provides advanced multiplex assays that streamline laboratory workflows, catering to a diverse range of research institutions and clinical laboratories across its primary hubs in Austin, London, and Sydney. By integrating automation with sophisticated molecular biology, SpeeDx enables researchers to achieve higher productivity and precision in their diagnostic processes, effectively bridging the gap between complex genomic data and actionable laboratory insights.
How much funding has SpeeDx raised?
SpeeDx has raised a total of $10M across 1 funding round:
Private Equity
$10M
Private Equity (2019): $10M with participation from Northpond Ventures
Key Investors in SpeeDx
Northpond Ventures
A prominent venture capital firm specializing in early-to-growth stage investments within the life sciences, diagnostics, and healthcare technology sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for SpeeDx?
With this major enterprise-level funding, SpeeDx is poised to scale its operational footprint and deepen its research and development capabilities. The strategic allocation of this capital will likely focus on the commercialization of next-generation diagnostic tools and the expansion of its global supply chain to meet the rising demand for rapid, accurate infection screening. As the company continues to refine its qPCR-based solutions, it remains focused on maintaining its competitive edge in the molecular diagnostics market, potentially exploring new therapeutic areas and diagnostic applications that require high-sensitivity detection methods. The firm's trajectory suggests a sustained commitment to innovation, aiming to set new benchmarks for efficiency and reliability in the global diagnostic ecosystem.
See full SpeeDx company page
